Top accelerator startups

14,448 startups · 29 programs

Valink Therapeutics

Active · Discovering bispecific antibody drug-conjugates (BsADC) against cancer

10signal of 100 · rising 2
  • team of 15Team size · YC's directory+6.2
  • went through YCProgram · this site+4

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from W21

All of W21

About Valink Therapeutics

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

YC batch
W21 · Winter 2021
Status, per YC
Active
Category
Other
Team size
15
Location
Boston, MA, USA
Checked
7h ago

YC tags: Biotech, Therapeutics, Drug discovery

Valink Therapeutics in W21: 336 companies, 30% AI

Valink Therapeutics: questions

Which YC batch was Valink Therapeutics in?

Valink Therapeutics was in Y Combinator's Winter 2021 batch (W21).

Is Valink Therapeutics still active?

Y Combinator lists Valink Therapeutics as active.

Where is Valink Therapeutics based?

Valink Therapeutics lists Boston, MA, USA as its location on YC's directory.